Results 101 to 110 of about 19,704 (200)

New standards in hypertension and cardiovascular risk management: focus on telmisartan

Vascular Health and Risk Management, 2010
Domenico Galzerano1, Cristina Capogrosso4, Sara Di Michele2, Antonio Galzerano1, Paola Paparello1, Diana Lama3, Carlo Gaudio21Department of Cardiology, San Gennaro Hospital, Naples, Italy; 2Department of Heart and Great Vessels, A.
Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al   +3 more
doaj  

A Validated Reversed-Phase HPLC Method for the Determination of Atorvastatin Calcium in Tablets [PDF]

, 2014
A Reversed-Phase Liquid Chromatographic (RP-LC) assay method was developed for the quantitative determination of atorvastatin calcium in the presence of its degradation products.
Ferello, L., Repetto, M. F., Segall, Adriana Ines, Simionato, Laura Daniela, Stamer. S., Zubata, P. D.   +5 more
core  

Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation

Diabetes, Metabolic Syndrome and Obesity, 2015
Akihiro Tojo, Saaya Hatakeyama, Satoshi Kinugasa, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan Abstract: The kidney plays an important role in gluconeogenesis during starvation.
Tojo A, Hatakeyama S, Kinugasa S, Nangaku M   +3 more
doaj  

PRoFESS [PDF]

, 2009
Lees, K.R.
core   +1 more source

Cardioprotective Effects of Telmisartan against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis

International Journal of Biological Sciences, 2011
Angiotensin-converting enzyme-2 (ACE-2) is a homolog of ACE that preferentially forms angiotensin-(ANG)-1-7 from angiotensin II (ANG II). We investigated the cardioprotective effects of telmisartan, a well-known angiotensin receptor blockers (ARBs ...
Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Ken'ichi Yamaguchi, Arun Prasath Lakshmanan, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe
doaj  

Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? [PDF]

, 2008
McInnes, G.T.
core   +2 more sources

Markers of diabetic nephropathy in patients with arterial hypertension III stage and type 2 diabetes mellitus and their correction [PDF]

, 2017
Метою нашої роботи було дослідження маркерів діабетичної нефропатії у пацієнтів із артеріальною гіпертензією та цукровим діабетом 2 типу та порівняння нефропротекторних властивостей антигіпертензивних препаратів для відбіру найоптимальнішого.
Chernatska, Olha Mykolaivna, Demikhova, Nadiia Volodymyrivna, Голубовська, Ф.Б., Демихова, Надежда Владимировна, Деміхова, Надія Володимирівна, Удовиченко, С.Я., Чернацкая, Ольга Николаевна, Чернацька, Ольга Миколаївна   +7 more
core  

Comparative evaluation of sacubitril/valsartan and telmisartan in the management of heart failure with reduced ejection fraction: an assessment of therapeutic effectiveness and safety profile

MGM Journal of Medical Sciences
Background: Heart failure (HF) remains a leading global cause of morbidity, hospitalizations, and mortality. Although sacubitril/valsartan has shown superior clinical outcomes compared with conventional angiotensin II receptor blockers, its higher cost ...
Sneha Biju, Alina Thomas, Merlin S. Mathew, Lakshmi Ramachandran, Daisy P. Augustine, Sujith Kumar   +5 more
doaj   +1 more source

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [PDF]

J Immunother Cancer
Murray CE, Ontiveros CO, Wentworth J, Blinkiewicz P, Leung B, Bai H, Spicer N, Holtz A, Tanner C, Balasubramanian A, Li W, Dray E, Zhao W, Curiel TJ.   +13 more
europepmc   +1 more source

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. [PDF]

Hypertension
Ahn JC, Lee CW, Ahn JH, Lim KH, Sohn IS, Sung KC, Kim KH, Bae JH, Hong SP, Jang WY, Jo SH, Han SH, Kim JB, Lee CJ, Lee JH, Kim N, Cho EJ, Sung JH, Ahn HS, Kim SY, Shin J, Seo SM, Hong SJ, Kim W, Park CG.   +24 more
europepmc   +1 more source